- Genus and Caribou Biosciences have announced a multi-year strategic collaboration where Genus receives a worldwide, exclusive licence to Caribou's leading CRISPR-Cas9 gene editing technology platform in certain livestock species.

This is a significant move for Genus and marks the largest technology-driven alliance that Genus has made to date.

The partnership positions Caribou at the forefront of an emerging market for which CRISPR-Cas9 could have profound benefits to animal welfare and society.

At 9:24am: [LON:GNS] Genus PLC share price was -42.5p at 1527.5p

Story provided by